11/19
09:31 am
afmd
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/15
09:11 am
afmd
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "hold" rating on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "hold" rating on the stock.
11/15
08:02 am
afmd
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/14
06:30 am
afmd
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Low
Report
Affimed Reports Third Quarter 2024 Financial Results & Business Update
11/6
06:30 am
afmd
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Medium
Report
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
11/5
09:00 am
afmd
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
High
Report
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
9/10
06:30 am
afmd
Affimed to Present at the Cantor Global Healthcare Conference 2024
Low
Report
Affimed to Present at the Cantor Global Healthcare Conference 2024
9/9
01:03 pm
afmd
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/6
08:08 am
afmd
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/5
06:30 am
afmd
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Low
Report
Affimed Reports Second Quarter 2024 Financial Results & Business Update
9/3
07:45 am
afmd
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Medium
Report
Affimed Appoints Shawn M. Leland as Chief Executive Officer
8/29
06:30 am
afmd
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Medium
Report
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024